News

/News/

Hamilton Thorne Announces Acquisition of Gynemed GmbH & Co.

By | April 28th, 2017|Uncategorized|

Click here to read the full press release. Source: Newswire - April 28, 2017 BEVERLY, MA and TORONTO, ON -- (April 28, 2017) - Hamilton Thorne Ltd. (TSX VENTURE: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research [...]

Medicenna Therapeutics takes the capital pool company route to going public – Financial Post

By | March 15th, 2017|Financing, News|

  Medicenna Therapeutics' recent CPC transaction is featured in the Financial Post. Click on the image above for the article.    

Q4 and Annual Share Price Performance in 2016 – Part 3

By | January 26th, 2017|Analysis, Blog, Capital Markets|

Tier 2 Canadian Healthcare Companies – same as Tier 1, not a good year In this blog, I am going to comment on the Q4 and annual 2016 share price performances of the group of 52 companies which ended 2016 in Tier 2 (there were 58 companies with share prices of $1.00 or more to [...]

Q4 and Annual Share Price Performance in 2016 – Part 2

By | January 24th, 2017|Analysis, Blog, Capital Markets|

Tier 1 Canadian Healthcare Companies – not a good year In this blog, I am going to comment on the Q4 and 2016 annual performances of the group of 51 companies which ended 2016 in Tier 1 (there were 57 companies with share prices of $1.00 or more to start 2016).   Q4 2016 Performance [...]

Q4 and Annual Share Price Performance in 2016 – Part 1

By | January 23rd, 2017|Analysis, Blog, Capital Markets|

For the analysis of the 2016 share price performance for the Canadian healthcare sector, there were 115 companies starting 2016 with share prices of $0.10 or higher. Twelve of these companies were no longer in the sector by the end of 2016, with six lost through acquisition/merger transactions. For the remaining 103 companies, the sector [...]

Apollo shrugged: Don’t Cross That Line – Contradictions in Provincial Pharmacare

By | October 25th, 2016|Apollo Shrugged, Blog, Commentary|

 Don’t Cross That Line – Contradictions in Provincial Pharmacare I’m in the middle of moving from Nova Scotia to Prince Edward Island and all that entails. I am aware that we’re fiercely proud of our provincial cultural differences here in the Maritimes (try debating who has the best lobster) so I expect a few things [...]

Q3 2016 – Share Price Performance – Part 3

By | October 24th, 2016|Analysis, Blog, Capital Markets|

Tier 2 Canadian Healthcare Companies – better performance than the Tier 1 companies In this blog, I am going to comment on the Q3 and 9-month 2016 share price performance of the group of 57 companies with share prices of between $0.10 and $0.99 to start 2016 (DiagnoCure is not included).   Advancers outnumbered decliners [...]

Q3 2016 – Share Price Performance – Part 2

By | October 21st, 2016|Analysis, Blog, Capital Markets|

Tier 1 Canadian Healthcare Companies – a very healthy bounce back In this blog, I am going to comment on the Q3 and 9-month performances of the group of 54 companies with share prices of $1.00 or more to start 2016 (Stellar Biotechnologies, Prism Medical and Transition Therapeutics dropped from assessment).   Advancers outnumbered decliners [...]

Q3 2016 – Share Price Performance – Part 1

By | October 20th, 2016|Analysis, Blog, Capital Markets|

Improved, positive performance in Q3 Overall, Q3 2016 share price performance in the sector was much better than in Q2 for the companies starting 2015 with share prices of $0.10 or higher. Two more companies have been deleted from the analysis in Q3 – Transition Therapeutics was acquired by OPKO Health and Prism Medical was [...]

Bloom Burton & Co. Strengthens Leadership with the Appointment of Shawn Aspden as Managing Director

By | September 6th, 2016|Bloom Burton, HR Changes, News|

TORONTO, September 6, 2016 - Bloom Burton & Co. Limited (“Bloom Burton”), Canada’s leading healthcare-specialized investment banking firm, is pleased to announce the appointment of Shawn Aspden as Managing Director of the firm. Mr. Aspden, CFA®, is a highly respected 20-year veteran of the Canadian capital markets, having most recently served as Vice Chairman and [...]